Canaccord Genuity Group Increases Atara Biotherapeutics (NASDAQ:ATRA) Price Target to $21.00

Atara Biotherapeutics (NASDAQ:ATRA) had its price target upped by equities research analysts at Canaccord Genuity Group from $13.00 to $21.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price objective suggests a potential upside of 64.45% from the company’s current price.

A number of other research analysts have also issued reports on the stock. The Goldman Sachs Group reduced their target price on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a research note on Wednesday, July 17th. Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and reduced their price objective for the stock from $25.00 to $18.00 in a research report on Friday, August 16th. Finally, HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Atara Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $16.67.

Atara Biotherapeutics Trading Down 10.4 %

Shares of Atara Biotherapeutics stock opened at $12.77 on Wednesday. The stock has a market capitalization of $62.70 million, a price-to-earnings ratio of -0.50 and a beta of 0.50. Atara Biotherapeutics has a twelve month low of $6.50 and a twelve month high of $39.50. The business’s 50 day simple moving average is $8.95 and its 200-day simple moving average is $10.32.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same period in the prior year, the business earned ($16.50) earnings per share. Sell-side analysts predict that Atara Biotherapeutics will post -12.09 earnings per share for the current year.

Institutional Trading of Atara Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ATRA. Redmile Group LLC boosted its holdings in shares of Atara Biotherapeutics by 1.7% in the first quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock valued at $6,429,000 after acquiring an additional 156,863 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Atara Biotherapeutics by 8,916.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after purchasing an additional 4,903,159 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Atara Biotherapeutics by 49.5% during the 1st quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock valued at $1,830,000 after purchasing an additional 873,133 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Atara Biotherapeutics by 29.3% during the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 86,842 shares during the period. Finally, Vestal Point Capital LP raised its stake in shares of Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after buying an additional 12,677 shares in the last quarter. 70.90% of the stock is currently owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.